多索茶碱联合布地奈德治疗支气管哮喘的临床疗效及对血清凋亡因子及炎症因子水平的影响

Observation of the clinical efficacy of doxofylline combined with budesonide on bronchialasthma,serum apoptosis factors and inflammatory factors

目的探究多索茶碱联合布地奈德对支气管哮喘的临床疗效及对血清细胞凋亡因子、炎症因子水平的影响。方法选取2019年1月至2020年1月该院收治的124例支气管哮喘患者为研究对象。将所有患者根据入院顺序随机分为研究组和对照组,每组62例。对照组予以布地奈德吸入剂治疗,研究组在对照组的基础上加服多索茶碱治疗,两组患者治疗周期均为4周。评估两组患者的临床疗效和肺功能相关指标,检测两组治疗前后血清凋亡因子B淋巴细胞瘤-2(Blc-2)、可溶性脂肪酸合成酶(sFas)和炎症因子白细胞介素(IL)-16、白介素-17(IL-17)、血清肿瘤坏死因子-α(TNF-α)的水平,对研究组患者茶碱血药水平进行监测,并记录患者在治疗期间产生的不良反应。结果研究组患者治疗总有效率为95.16%,高于对照组的85.48%,差异有统计学意义(P<0.05),治疗后研究组肺功能各指标一秒用力呼气容积(FEV1)、用力肺活量(FVC)及呼气流量峰值(PEF)与对照组比较,差异有统计学意义(P<0.05)。研究组治疗后血清凋亡相关因子Blc-2、sFas水平均低于对照组,且差异有统计学意义(P<0.05)。研究组血清炎症因子IL-6、IL-17、TNF-α水平在治疗后明显低于对照组,差异有统计学意义(P<0.05)。在治疗期间,研究组患者茶碱平均血药水平为(7.25±2.04)μg/mL,不良反应总发生率为6.45%,与对照组(4.84%)比较,差异无统计学意义(P>0.05)。结论多索茶碱联合布地奈德对支气管哮喘的治疗安全有效,能明显改善肺功能,有效降低血清凋亡因子和炎症因子水平,可推广应用。

Objective To investigate the clinical effect of doxofylline combined with budesonide on bronchial asthma and its influence on the levels of apoptosis factors and serum inflammatory factors.Methods A total of 124 patients with bronchial asthma admitted to the hospital from January 2019 to January 2020 were selected as the research objects.All patients were randomly divided into study group and control group according to the order of admission,with 62 people in each group.The control group was treated with budesonide inhalation,and the study group was treated with doxofylline on the basis of the control group.The treatment period of both groups was 4 weeks.The clinical efficacy and lung function-related indicators of the two groups of patients were evaluated,the levels of serum apoptosis factors B-lymphoma-2(Blc-2),soluble fatty acid synthase(sFas)and inflammatory factors interleukin(IL)-16,IL-17,serum tumor necrosis factor-α(TNF-α)before and after treatment in the two groups were detected,and the patient′s adverse reactions during treatment were recorded.Results The total effective rate of patients in the study group was 95.16%,which was higher than 85.48%in the control group,and the difference was statistically significant(P<0.05).The difference was statistically significant(P<0.05).After treatment,the lung function indexes forced expiratory volume in the first second(FEV1),forced vital capacity(FVC)and peak value expiration velocity of flow(PEF)in the study group were different from those in the control group(P<0.05).After treatment,the expression levels of serum apoptosis-related factors Blc-2 and sFas in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The serum inflammatory factors IL-6,IL-17 and TNF-αin the study group were significantly lower than those in the control group after treatment,and the differences were statistically significant(P<0.05).During the treatment period,the average serum concentration of theophylline in the study group was(7.25±2.04)μg/mL.The total incidence of adverse reactions in the study group was 6.45%,compared with the control group(4.84%),the difference was not statistically significant(P>0.05).Conclusion Doxofylline combined with budesonide is safe and effective in the treatment of bronchial asthma.It could significantly improve lung function,effectively reduce the levels of apoptosis factors and inflammatory factors,which could be widely used.